Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Tysabri (Natalizumab) Targets Molecule Crucial for Type of B-Cell to Accumulate in the Brain

Mice with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), were found to have milder symptoms if the target of natalizumab (Tysabri) — VLA4 — was absent on B-cells, preventing regulatory cells that might control immune processes from entering the brain.

B-cells are increasingly thought to play a role in autoimmune processes in the brain. Earlier studies have also shown that Bregs, a type of B-cell with regulatory properties, might be involved in suppressing EAE.

VLA4 is a molecule expressed on the surfaces of B-cells and the target of natalizumab. The expression of the molecule has been shown to mediate important steps in the autoimmune process: when VLA4 is blocked, fewer B-cells accumulate in the brain during EAE, suggesting that natalizumab works in RRMS in part by blocking B-cell accumulation.

B-cell actions, however, are complex, being composed of both immune mediating and immune controlling cells.

Researchers at the University of California, San Francisco, explored if VLA4 was also an important factor in allowing Bregs to accumulate in the brain, speculating that the lack of Bregs in mice might explain their more severe EAE symptoms.

In the study, “CNS accumulation of regulatory B cells is VLA-4-dependent,“ researchers studied EAE in mice lacking VLA4 on B-cells using two different techniques. One method was dependent on the activation of B-cells while the other was not.

Their findings, presented in the journal Neuroimmunology and Neuroinflammation, showed that in mice lacking VLA4, EAE was less severe than in control mice when the researchers used the B-cell dependent method. In contrast, animals got sicker when EAE was induced by the B-cell independent method.

In mice lacking the natalizumab target having B-cell independent EAE, researchers noted that fewer B-cells had accumulated in the central nervous system. Particularly, the team found that virtually no Bregs had entered the brains of the mice with more severe EAE.

The findings underscore the complexity of autoimmune processes in MS. While researchers speculate that natalizumab might function by preventing brain B-cell–mediated immune reactions, the experiments showed that preventing regulatory B-cells from entering the brain produces more severe symptoms.

Because VLA4 is also present on immune T-cells, researchers are still ultimately in the dark regarding the contributions of the various cell types to MS. The study, however, provides evidence that Bregs counteract the autoimmune processes, at least in mice, and highlights the need to choose the right EAE model when studying B-cell processes.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News